Drug rebates will remain… but so will pressure to reduce drug prices and demonstrate value

0
34

On July 10, the White House abandoned efforts to eliminate safe-harbor protections for drug rebates in Medicare Part D and Medicaid managed care due to concerns that the change would lead to higher premiums for beneficiaries. (For background on this issue, see our previous blogs.) While the rebate issue is now off the table,

The post Drug rebates will remain… but so will pressure to reduce drug prices and demonstrate value appeared first on Deloitte Center for Health Solutions.